产品说明书
Tenofovir alafenamide fumarate
 |
同义名 : | GS-7340 fumarate;TAF fumarate |
| CAS号 : | 379270-38-9 | |
| 货号 : | A167277 | |
| 分子式 : | C25H33N6O9P | |
| 纯度 : | 98% | |
| 分子量 : | 592.538 | |
| MDL号 : | MFCD28167823 | |
| 存储条件： |
粉末 Inert atmosphere,2-8°C 液体 -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 35 mg/mL(59.07 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO H2O: 25 mg/mL(42.19 mM) |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | GS-7340 Fumarate (tenofovir alafenamide: TAF) is a novel nucleotide reverse transcriptase inhibitor for the treatment of HIV-1 infection that has efficacy similar to that of TDF (tenofovir disoproxil fumarate) and improved safety compared with TDF[3]. Compared with 300 mg TDF, TAF demonstrated more potent antiviral activity, higher peripheral blood mononuclear cell intracellular tenofovir diphosphate levels, and lower plasma TFV exposures, at approximately 1/10th of the dose[4]. TAF has a much lower risk of kidney toxicity or bone density changes than TDF, and also offers long-term potential in the pre-exposure prophylaxis (PrEP) of HIV infections. TAF is specifically accumulated in lymphatic tissue, and in the liver, and hence also holds great potential for the treatment of hepatitis B virus (HBV) infections[5]. | ||
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
1.69mL 0.34mL 0.17mL |
8.44mL 1.69mL 0.84mL |
16.88mL 3.38mL 1.69mL |
| 参考文献 |
|---|